Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.

Abstract: Based on the structural features of KIR full genomic sequences, the distribution of single nucleotide polymorphisms in their coding regions and the length of flanking intronic sequence of each exon, a method for high-throughput simultaneous sequence-based typing of all the 14 functional killer cell immunoglobulin-like receptor (KIR) genes is disclosed including: developing a scientific and reasonable polymerase chain reaction (PCR) amplification strategy; simultaneously amplifying the complete coding sequence of each functional KIR gene using 3˜5 pairs of KIR gene-specific PCR primers that have similar annealing temperature; and determining the nucleotide sequences of the exons carried by each PCR amplicon in both directions using the forward and reverse sequencing primers, respectively, as shown in FIG. 1.

Abstract: Disclosed are a human rare blood type detection method, a kit, a rapid screening method and applications thereof. By using multiple pairs of PCR specific primers directing to the SNP loci of multiple rare blood types, the SNP loci of multiple rare blood types are simultaneously detected in the same PCR reaction system; and the multiplex PCR detection method and a Pool detection method are combined to rapidly screen the human rare blood types.

Abstract: A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.

Abstract: A method for measuring blood levels of ? cell DNA that is released upon ? cell death by using a quantitative probe technology to detect amplified methylated and demethylated forms of the insulin gene DNA, representing normal tissue and ? cell specific origin, respectively. Using probes permits the sensitive and specific identification of demethylated insulin DNA patterns that are present only in ? cells. The method offers a bioassay for detecting ? cell loss in diabetes, useful for screening of prediabetes, monitoring of disease progression, and selection and monitoring of therapies. The technique finds potential use in both Type I and Type II diabetes, as well as gestational diabetes.

Abstract: A method is provided for determining the zygosity of an Rf4 gene in a corn plant. A method may include performing a first PCR assay, a second PCR assay, quantifying probes used in the first and second PCR assays, and comparing the quantified probes to determine zygosity.

Abstract: The present invention is concerned with a method of rapid identification of a mammalian species origin or mammalian species origins of a sample.

Abstract: The invention provides recombinant DNA molecules that are unique to the maize MON 87419 event and transgenic maize plants, plant parts, seeds, cells, and agricultural products containing the MON 87419 event as well as methods of using and detecting the maize MON 87419 event. Transgenic maize plants containing the MON 87419 event exhibit tolerance to dicamba and glufosinate herbicides.

Abstract: The current disclosure generally relates to the field of saxitoxins and the identification of microorganisms capable of producing them. In particular, the saxitoxin A (sxtA) gene comprising catalytic domain sequences saxitoxin A1 (sxtA1) and saxitoxin A4 (sxtA4) is identified in a number of dinoflagellate species. The disclosure relates to methods of detection of saxitoxin-producing dinoflagellates by amplification and detection of the sxtA gene (in particular by PCR) and kits and primers for use in the method are also disclosed. Saxitoxin-producing dinoflagellate genera detected by the method include Alexandrium, Pyrodinium or Gymnodinium.

Abstract: A primer for the amplification of a DNA template comprising a protelomerase target sequence, particularly for production of closed linear DNA, which primer is capable of specifically binding to a palindromic sequence within a protelomerase target sequence and priming amplification in both directions.

Abstract: A primer and method for amplification of a target nucleic acid, the primer adapted to conform into a conformation that dissociates from a complementary strand of DNA duplex. The conformation may have a free energy with more favorable thermodynamics than a corresponding DNA duplex, such as a B-DNA duplex. The dissociation may occur during an extension step of an amplification method, such as polymerase chain reaction. The method can proceed isothermally, and the primers may include intrinsic fluorescence.

Abstract: Methods and compositions for detecting, identifying, and quantifying Brassica A genomic DNA are described. The methods are specific to the Brassica A genome and do not cross-react with other Brassica species, crops or weedy relatives that could contribute to contamination of a canola field.

Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.

Abstract: The present invention pertains to: a method for modifying a nucleic acid contained in a sample, the method including a step for bringing the sample into contact with a nucleic acid-modifying agent in the presence of an acidic polysaccharide and/or a nucleotide; and a method for selectively detecting a nucleic acid derived from living cells contained in the sample, the method including the following steps: (a) a step for modifying a nucleic acid contained in a sample according to the method for modifying a nucleic acid contained in a sample, which includes a step for bringing the sample into contact with a nucleic acid-modifying agent in the presence of an acidic polysaccharide and/or a nucleotide; and (b) a step for selectively detecting an unmodified nucleic acid from the sample after step (a). The present invention further pertains to a kit and composition for use in these methods.

Abstract: Provided is a method of preparing nucleic acid molecules comprising: (a) a step of providing nucleic acid fragments constituting at least a portion of the complete sequence of a target nucleic acid; (b) tagging the nucleic acid fragments with barcode sequences; (c) identifying the sequence of the nucleic acid fragments tagged by the barcode sequences; and (d) recovering desired nucleic acid fragments among the sequence-identified nucleic acid fragments using the barcode sequences.

Abstract: The determination of the nucleotide sequence of HIV-1 DNA; identification, isolation and expression of HIV-1 DNA sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HIV-1.

Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.

Abstract: Embodiments of the invention relate generally to ex vivo methods of quantifying expression of interferon responsive genes and characterizing an individual's potential responsiveness to interferon administration. Certain embodiments relate to methods to monitor the efficacy of ongoing interferon therapy by evaluating expression of interferon responsive genes before and after interferon administration.

Abstract: A method for operating a nucleic acid sequencing instrument with movable flow cells. The method includes providing a flow cell having a flow path with an inlet port and an outlet port and filling the flow path, from the inlet port to the outlet port, with a first liquid reagent. The method also includes providing a station block having an inlet passage and an outlet passage, mounting the flow cell on the station block with the inlet port in fluid communication with the inlet passage and the outlet port in fluid communication with the outlet passage, introducing a gaseous bubble into the inlet port, conveying a second liquid reagent from the inlet passage into the inlet port to move the gaseous bubble through the flow path and into the outlet passage and fill the flow passage with the second liquid reagent, and removing the flow cell from the station block.

Abstract: Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed.